Viglya wishes to establish transparent and open communication with its stakeholders. This section offers new and updated information regarding the company and the life science sector.


AEMPS: Solicitudes de autorización de comercialización de medicamentos de uso humano. Monográfico de bases legales

Sorry, this entry is only available in Español.


Comments are closed.

EMA: Facilitating the development of advanced therapies
UK MHRA: Drug Safety Update (June 2015)
EMA: Update on publication of clinical data
EMA fast-tracks enzyme replacement therapy for lysosomal acid lipase deficiency
EMA: First treatment recommended for rare bone disease
EMA: First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU
Viglya Summer Crossword Solution
EMA: Meeting highlights from the CHMP 22-25 June 2015
EMA: First medicine recommended for approval for hidradenitis suppurativa
EMA: Better training tools recommended to support patients using adrenaline auto-injectors